

January 09, 2025

To,
The Manager
Dept of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001

Dear Sir/Madam,

Subject : Outcome of the Board Meeting

Reference: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)

Regulation, 2015

Scrip : 511509

With reference to the above cited subject and our letter dated January 02, 2025 and January 04, 2025, we bring to your kind notice that the Board of Directors of the Company at their meeting held today, i.e. Thursday, January 09, 2025, *inter-alia*, transacted the following business:

- 1. Approved the Un-Audited Standalone & Consolidated Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2024.
- 2. Approved Raising of Funds by Preferential Issue of Convertible Equity Warrants to Certain Identified Promoter/Promoter Group and Non-Promoter Group/Entities.

The issuance and allotment of up to 1,00,00,000 (One Crore only) Convertible Equity Warrants ('Warrants'), carrying a right exercisable by Proposed Allottees to subscribe to one Equity Share (having face value of Rs. 10/- (Rupees Ten only)) per Warrant by way of preferential allotment on private placement basis to "Promoter/Promoter Group and Non-Promoter(Public Category)" ("Proposed Allottees"), as detailed below, at an issue price of Rs. 45/- (Rupees Forty-Five only) per Warrant, which is higher than the floor price determined in accordance with the provisions of Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations") payable in cash for an amount aggregating up to Rs. 45,00,00,000/- (Rupees Forty-Five Crore only) in such manner and on such terms and conditions as may be determined by the Board in accordance with SEBI ICDR Regulations and other applicable laws subject to approval of Members at the ensuing Extraordinary General Meeting and other necessary regulatory, statutory and other approvals, permissions and sanctions, as may be applicable.



Names of the Proposed Allottees of the Convertible Equity Warrants:

S.No.	Names of the Proposed Allottees	Category	Maximum no. of
			Warrants for the
			respective Allottee
1.	Viswanath Kompella	Promoter	6,00,000
2.	Kompella Lopa Mudra	Promoter Group	6,00,000
3.	Kompella Ramakrishna Paramahamsa	Promoter Group	6,00,000
4.	Kompella Modini	Promoter Group	6,00,000
5.	Dwight Technologies Private Limited	Public	25,00,000
6.	Paraj Infrastructures Private Limited	Public	25,00,000
7.	Antique Infotech Private Limited	Public	26,00,000
		Total	1,00,00,000

Details as required under Regulation 30 of the Listing Regulations read with Master Circular issued by SEBI vide circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 ("Master Circular"), with respect to the preferential issue is enclosed as Annexure-I.

3. Approved Notice of the Extra-Ordinary General Meeting (EGM No. 01/2024-2025), which is scheduled to be held on Friday, February 07, 2025 at 12:30 P.M. (noon) for obtaining the approval of the Members of the Company for the aforementioned matters, the Board of Directors of the Company has decided to hold an EGM of the Company on Friday, February 07, 2025 through OAVM/VC and has approved the draft notice of the EGM and matters related thereto to be issued to the shareholders for convening the EGM.

The notice of the said EGM will be sent separately to the stock exchange(s) and to the shareholders of the Company and will also be available on the Company's website at www.vivobio.com and on the website of the stock exchange i.e. BSE Limited in due course.

4. The Company has fixed Friday, January 31, 2025 as the cut-off date for determining the eligibility of the Members entitled to vote by remote e-voting at the ensuing EGM of the Company schedule to be held on Friday, February 07, 2025 through OAVM/VC. The Company would be availing e-voting services of CDSL. The remote e-voting period begins on Monday, February 03, 2025 (09:00 A.M. IST) and ends on Thursday, February 06, 2025 (05:00 P.M. IST).



The meeting commenced at 05:30 p.m. and concluded at 06:25 p.m.
This is for your information and records.
Thanking You,
Yours faithfully
For Vivo Bio Tech Limited
A V Kiran Company Secretary
Encl as above



Annexure-I

Details as required under Regulation 30 of the Listing Regulations read with Master Circular issued by SEBI vide circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 ("Master Circular"), with respect to the preferential issue.

S.No.	Particulars	Disclosure			
1.	Type of securities proposed to be Issued	Fully Conve	ertible Equity Warra	ints ("Warra	nts")
2.	Type of issuance	Preferentia	ıl Issue		
3.	Total number of securities proposed to be issued or total amount for which the securities will be issued	of Rs. 45/- to "Prom Category)"	(Rupees Forty-Five oter/Promoter Gr	only) each oup and regating up	ants at an issue price to persons belonging Non-Promoter(Public to Rs. 45,00,00,000/-
4.	Name and number of the Investor(s)	S.No.	Names of the Proposed Allottees	Category	Maximum no. of Warrants for the respective Allottee
		1.	Viswanath Kompella	Promoter	6,00,000
		2.	Kompella Lopa Mudra	Promoter Group	6,00,000
		3.	Kompella Ramakrishna Paramahamsa	Promoter Group	6,00,000
		4.	Kompella Modini	Promoter Group	6,00,000
		5.	Dwight Technologies Private Limited	Public	25,00,000
		6.	Paraj Infrastructures Private Limited	Public	25,00,000
		7.	Antique Infotech Private Limited	Public	26,00,000
				Total	1,00,00,000
5.	Issue price	Rs. 45/- (Ru	upees Forty-Five on	ly)	
6.	Post allotment of				

Registered Office:, 3rd Floor, Ilyas Mohammed Khan Estate, 8-2-672/5&6, Road No.1, Banjara Hills, Hyderabad - 500034, Telangana, India; **Address of Preclinical Research Facility:** Sy.No.349/A, Pregnapur Village, Gajwel Mandal, Siddipet District, Telangana, INDIA; Pin:502311 Email Id: lnvestors@vivobio.com Phone# 040-23313288 Website: www.vivobio.com; CIN: L65993TG1987PLC007163

	securities - outcome of the	Category	Pre prefere issue	ential	Post prefero	
	subscription.		No of	%	No of	%
			Shares		Shares	
		Promoters	62,71,500	38.88	86,71,500	33.19
		and				
		Promoter				
		Group (A)				
		Public (B)	98,57,020	61.12	1,74,57,020	66.81
		Non-	0	0	0	0
		Promoter-				
		Non Public				
		Shareholding				
		(C)				
		Total (A) +	1,61,28,520	100	2,61,28,520	100
		(B)+(C)				
		* The above pos	st-issue shareh	olding is	prepared to ass	sume full
		conversion of V	Varrants into e	quity sha	ares issued pur	suant to
		this preferential	issue			
7.	Intimation on	The tenure of	the Warrants	shall no	t exceed 18 (e	eighteen)
	conversion of	months from the	he date of allo	tment. I	Each warrant v	vould be
	securities or on	convertible into			_	
	lapse of the	Warrants can be			•	
	tenure of the	(eighteen montl				
	instrument	In the event the				
		Warrants within	•		•	
		date of allotme				
		shall lapse and	•	•		older on
		such Warrants s	hall stand forfe	ited by tl	ne Company.	
8.	Nature of	Cash				
	Consideration					
9.	Any cancellation	Not applicable				
	or termination of					
	proposal for					
	issuance of					
	securities					
	including reasons					
	thereof					

Vivo Bio Tech Ltd.
Your Drug Discovery Partner

Vivo Bio Tech Limited 3rd Floor, Ilyas Mohammed Khan Estate, #8-2-672/5&6 Road No.1, Banjara Hills, Hyderabad-500034, Telangana E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

	UN-AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE THIRD QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2024	JLTS FOR THE THIRI	D QUARTER & NINI	E MONTHS ENDED	31ST DECEMBER, 2	2024	
		100				-	Rs. in Lacs
7			QUARTER ENDED		NINE MONTHS ENDED	4S ENDED	YEAR ENDED
S.No.	PARTICULARS	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
_	Revenue from operations	1,221.25	1,203.51	1,284.89	3,438.18	3,369.29	4,545.12
=	Other Income	0.85	463.10	2.97	465.18	2.97	3.88
Ξ	Total Income	1,222.10	1,666.61	1,287.86	3,903.36	3,372.26	4,549.00
≥	Expenses						
	a) Increase/(decrease) in stock in trade and WIP	103.25	57.06	-19.67	177.52	-72.32	-80.13
	b) Consumption of Raw materials		. 1	1		1	-
	c) Purchase of traded goods	83.35	90.57	117.72	324.48	355.93	465.10
	d) Employees Cost	321.64	344.34	294.95	900.23	799.97	1,068.31
	e) Depreciation and amortisation	224.77	229.41	227.65	677.11	686.47	929.08
	f) Finance Cost	183.76	206.11	222.17	582.31		777.79
	g)Administrative Expenditure	159.14	152.41	254.20	486.55		982.81
	Total	1,075.91	1,079.90	1,097.02	3,148.19	3,109.68	4,142.96
>	Profit Before Tax & Exceptional Item (III-IV)	146.19	586.71	190.84	755.16	262.58	406.04
	Expceptional Items			9	3	1	3
	Prior Period Items	а	ì	1	1	1	,
>	Profit Before Tax	146.19	586.71	190.84	755.16	262.58	406.04
5	Tax Expense				20		
	a. Current Tax	61.38	78.18	59.65	159.38	94.62	167.71
	b. Deffered tax	2.81	(14.83)	(0.89)	(26.21)	(11.06)	(14.29)
	Total Tax Expense	64.19	63.35	58.76	133.17	83.56	153.42
	Net Profit After Tax (V-VI)	82.00	523.36	132.08	621.99	179.02	252.62
≡ ∧	Minority Interest						•
×	Other Comprehensive Income						
	a.Items that will be reclassified to profit or loss (Net of Tax)	I	-	ı		T	7
×	Total other Comprehensive Income(VII+VIII+IX)	82.00	523.36	132.08	621.99	179.02	252.62
₹	Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)	1,612.85	1490.35	1490.35	1,612.85	1490.35	1,490.35
×	Earnings per equity share:				37		
	1)Basic	0.55	3.51	0.89	4.16		1.70
	2)Diluted	0.55	3.51	0.89	4.16	1.20	1.51
-	Discontinuo de la compania	٠				For Vivo Rio Tech Limited	h limited
Date: Jai	ridee: Hyderabau Date: January 09, 2025			W.	CH	1	1
				0		3	
				OVH HAYD	HYDERABAD [5]	M. Kalvan Ram	
			28	01	TE	Whole Time Director	ector
*					3	DIN:02012580	*

E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163 Road No.1, Banjara Hills, Hyderabad-500034, Telangana 3rd Floor, Ilyas Mohammed Khan Estate, #8-2-672/5&6 Vivo Bio Tech Limited

Your Drug Discovery Partner Vivo Bio Tech Ltd.

Revenue from operations Other Income Total Income Expenses a) Increase/(decrease) in stock in trace) b) Consumption of Raw materials c) Purchase of traded goods d) Employees Cost e) Depreciation and amortisation f) Finance Cost g) Administrative Expenditure Total Profit Before Tax & Exceptional Items (II Exceptional Items Prior Period Items Profit Before Tax Tax Expense a. Current Tax b. Deffered tax Total Tax Expense a. Current Tax b. Deffered tax Total Tax Expense a. Current Tax be not the Profit After Tax (V-V Other Comprehensive Income a. Items that will be reclassified to profit and Up Share Capital (Face value of Rs. Earnings per equity share: 1)Basic 2)Diluted		UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE THIRD QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2024	S FOR THE THIRD O		2011			
PARTICULARS 31.12.2024 31.12.2023 31				£				Rs. in Lac
Revenue from operations PARTICULANS 31.12.2024 31.02.2024 31.12.2023 31.12.2023 31.12.2023 31.12.2023 31.12.2023 31.12.2023 31.12.2023 31.12.2023 31.12.2023 31.12.2023 31.12.2023 44.58 31.12.2023 44.51 A.12.05.51 31.20.203 3.13.2023 4.43.81 A.12.05.51 4.20.51 3.20.51 4.20.51 4.43.81 A.12.05.51 4.43.81 A.12.05.31 A.12.05.32 A.12.05.31 A.12.05.32			ď	UARTER ENDED		NINE MON	THS ENDED	YEAR ENDED
Un-Audited Un-	No.	¥	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
State Stat			Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
Depreciation and amortisation 1,222.10 1,666.61 1,233.65 3,303.61 3,403.60 3,306.01 4,40 Submisses John Stock in trade and WIP	-	Revenue from operations	1,221.25	1,203.51	1,270.59	5	3,333.04	20
Decide D	=	Other Income	0.85	463.10			2.97	
Expenses Figure Repenses Figure Repenses Figure Repenses 103.25 57.06 -19.67 177.52 -72.32 -8 -19.67 -19.67 -19.67 -17.52 -72.32 -8 -8 -10.22	≡	Total Income	1,222.10	1,666.61	1,273.56			
103.25 57.06 1.957 1.77.52 2.8 2.9 10.0ccccccccccccccccccccccccccccccccccc	2	Expenses	7.					
b) Consumption of Raw materials c) Purchase of traded goods c) Sa. 33 4.48 c) Purchase of traded goods c) Sa. 33 4.48 c) Sa. 33 4.48 c) Purchase of traded goods c) Sa. 33 4.48 c) Sa. 33 6.41 c) Sa. 33 4.48 c) Sa. 33 6.41 c) Sa. 33 13. 70 c) Sa. 34 c) Sa. 37 13. 70 c) Sa. 37 13. 71 c) Sa.		a) Increase/(decrease) in stock in trade and WIP	103.25	57.06	-19.67	15		
c) Purchase of traded goods 83.35 90.57 117.72 324.48 355.93 46 d) Employees Cost 314.24 336.45 280.64 883.80 760.35 1,01 e) Depreciation and amortisation 123.77 229.41 227.17 582.31 655.95 777 f) Finance Cost 138.76 206.11 222.17 582.31 625.95 777 g) Administrative Expenditure 1,084.8 1,071.99 1,082.67 3,131.70 3,070.00 4,08 Exceptional Items 1,081.8 1,071.99 1,082.67 3,131.70 3,070.00 4,08 Prior Period Items 1,156.24 1,071.99 1,082.67 3,131.70 3,070.00 4,08 Prior Period Items 1,081.84 78.18 59.65 1,089 771.66 26.01 4,08 B. Defiered tax 1,041.9 1,082.9 771.66 26.01 4,08 1,089 1,146 1,146 1,146 1,146 1,146 1,146 1,146 1,146 1,146		b) Consumption of Raw materials	1		•			1
1,01 22,4.77 229,41 227,55 677,11 686,47 92 92 92 92 92 92 92 9		c) Purchase of traded goods	83.35	90.57	117.72			
Finance Cost		d) Employees Cost	314.24	336.45	280.64			
Figure Cost 183.76 206.11 222.17 582.31 625.95 773 73.62 73.		e) Depreciation and amortisation	224.77	229.41	227.65			
g) Administrative Expenditure 159.11 152.39 254.16 486.49 713.62 98 Experite Expenditure Total 1,068.48 1,071.99 1,082.67 3,131.70 3,070.00 4,08 Experite Before Tax Expense 153.62 594.62 190.89 771.66 266.01 40 Priorite Before Tax 153.62 594.62 190.89 771.66 266.01 40 Priorite Before Tax 153.62 594.62 190.89 771.66 266.01 40 Tax Expense 153.62 584.62 190.89 771.66 266.01 40 a. Current Tax 15.02 64.18 78.18 59.65 159.38 94.62 16 b. Deffered tax 15.02 132.31 132.13 132.13 132.13 132.13 132.13 132.13 132.45 15 Other Comprehensive Income 15.02 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,4		f) Finance Cost	183.76	206.11	222.17	•		
Total Economy Items Total Economy Items 1,068.48 1,071.99 1,082.67 3,131.70 3,070.00 4,08 Exceptional Items 1,53.62 594.62 190.89 771.66 266.01 40 Profit Performal Items - <td></td> <td>g) Administrative Expenditure</td> <td>159.11</td> <td>152.39</td> <td>254.16</td> <td></td> <td></td> <td></td>		g) Administrative Expenditure	159.11	152.39	254.16			
Profit Before Tax & Exceptional Items (III-IV) 133.62 594.62 190.89 771.66 266.01 40 Exceptional Items 1.33.62 594.62 190.89 771.66 26.01 40 Profit Before Tax 1.33.62 594.62 190.89 771.66 266.01 40 Profit Before Tax 1.33.62 594.62 190.89 771.66 266.01 40 Tax Expense 1.32.81 1.48.83 1.48.83 1.26.21 1.10.69 1.4 B. Deffered tax 2.81 1.48.83 6.3.85 58.76 1.10.69 1.5 Deffered tax 1.04.83 1.33.17 83.56 1.5 1.5 1.5 Deffered tax Net Profit After Tax (V-VI) 89.43 531.27 132.13 638.49 182.45 25 Other Comprehensive Income 1.512.85 1.490.35 1.490.35 1.490.35 1.490.35 1.490.35 1.490.35 1.490.35 1.490.35 1.490.35 1.490.35 1.490.35 1.490.35 1.490.35 1.49		Total	1,068.48	1,071.99	1,082.67			
Exceptional Items -	>	Profit Before Tax & Exceptional Items (III-IV)	153.62	594.62				
Profit Before Tax 133.62 594.62 190.89 771.66 266.01 40 Profit Before Tax 133.62 594.62 190.89 771.66 266.01 40 Tax Expense a. Current Tax 61.38 78.18 59.65 159.38 94.62 16 a. Current Tax b. Deffered tax 64.19 64.19 (1.83) (0.89) (26.21) (11.06) (1.65) D. Deffered tax Net Profit After Tax (V-VI) 89.43 531.27 132.13 638.49 182.45 25 Other Comprehensive Income Anternative Income (VIII+VIII) 89.43 531.27 132.13 638.49 182.45 25 Total other Comprehensive Income (VIII+VIII) 89.43 531.27 132.13 638.49 182.45 25 Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units) 1,612.85 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35<		Exceptional Items	•			•	1	•
Profit Before Tax 153.62 594.62 190.89 771.66 266.01 40 Tax Expense 61.38 78.18 59.65 159.38 94.62 16 a. Current Tax 64.19 78.18 59.65 159.38 94.62 16 a. Current Tax 2.81 (14.83) (0.89) (26.21) (11.06) 16 b. Deffered tax 1.01 89.43 531.27 132.13 83.69 182.45 25 Other Comprehensive Income a. Items that will be reclassified to profit or loss (Net of Tax) 89.43 531.27 132.13 638.49 182.45 25 a. Items that will be reclassified to profit or loss (Net of Tax) 89.43 531.27 132.13 638.49 182.45 25 paid Up Share Capital (Face value of Rs.10/-) (In lakh Units) 1,612.85 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,		Prior Period Items	1	1	1	1	1	1
Tax Expense 61.38 78.18 59.65 159.38 94.62 16 a. Current Tax a. Current Tax 2.81 (14.83) (0.89) (26.21) (11.06) (14.06) (14.06) (15.21) (11.06) (14.06) (15.21) (11.06) (14.06) (15.21) (15.06) (15.	5	Profit Before Tax	153.62	594.62	190.89			
a. Current Tax 61.38 78.18 59.65 159.38 94.62 16 b. Deflered tax c. 2.81 (1.4.83) (0.89) (26.21) (1.06) (1.40) (1.40) (1.40) <th< td=""><td>₹</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	₹							
b. Deffered tax 2.81 (14.83) (0.89) (26.21) (11.06) (12.05) Total Tax Expense 64.19 63.35 58.76 133.17 83.56 15 Other Comprehensive Income a.ltems that will be reclassified to profit or loss (Net of Tax) 89.43 531.27 132.13 638.49 182.45 25 Total other Comprehensive Income (VII+VIII) 89.43 531.27 132.13 638.49 182.45 25 Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units) 1,612.85 1,490.35 1,490.35 1,612.85 1,490.35		a. Current Tax	61.38	78.18				
Other Comprehensive Income a. Items that will be reclassified to profit or loss (Net of Tax) 89.43 531.27 132.13 638.49 182.45 25 Other Comprehensive Income a. Items that will be reclassified to profit or loss (Net of Tax) 89.43 531.27 132.13 638.49 182.45 25 Total other Comprehensive Income (VII+VIII) 89.43 531.27 132.13 638.49 182.45 25 Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units) 1,612.85 1,490.35 1,490.35 1,612.85 1,490.35		b. Deffered tax	2.81	(14.83)	(0.89)			
Other Comprehensive Income a. Items that will be reclassified to profit or loss (Net of Tax) 89.43 531.27 132.13 638.49 182.45 25 Total other Comprehensive Income (VII+VIII) 89.43 531.27 132.13 638.49 182.45 25 Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units) 1,612.85 1,490.35 1,490.35 1,612.85 1,490.35 1		Total Tax Expense	64.19	63.35	28			
Other Comprehensive Income Other Comprehensive Income (Net of Tax) 89.43 531.27 132.13 638.49 182.45 25 Total other Comprehensive Income (VII+VIII) 89.43 531.27 132.13 638.49 182.45 25 Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units) 1,612.85 1,490.35 1,490.35 1,612.85 1,490.35 <td></td> <td>Net Profit After Tax (V-VI)</td> <td>89.43</td> <td>531.27</td> <td>132.13</td> <td></td> <td>0.00</td> <td></td>		Net Profit After Tax (V-VI)	89.43	531.27	132.13		0.00	
a.ltems that will be reclassified to profit or loss (Net of Tax) Total other Comprehensive Income (VII+VIII) Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units) Earnings per equity share: 1)Basic 2)Diluted 23.1.27 132.13 638.49 182.45 1490.35 1,	₹							
Total other Comprehensive Income (VIII+VIII) 89.43 531.27 132.13 638.49 182.45 25 Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units) 1,612.85 1,490.35 1,490.35 1,612.85 1,490.35		a.Items that will be reclassified to profit or loss (Net of Tax)		-1	.1			,1
Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units) 1,612.85 1,490.35 1,612.85 1,612.85 1,490.35 1,490.35 1,612.85 1,490.35 1,290.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,290.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,490.35 1,290.35 1,490.35	×	Total other Comprehensive Income (VII+VIII)	89.43	531.27	132.13			
Earnings per equity share: 0.60 3.56 0.89 4.27 1.22 1)Basic 0.60 3.56 0.89 4.27 1.22	×	Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)	1,612.85	1,490.35	1,490.35			
0.60 3.56 0.89 4.27 1.22 0.60 3.56 0.89 4.27 1.22	≂	Earnings per equity share:						
0.60 3.56 0.89 4.27 1.22		1)Basic	09:0	3.56			1.22	
		2)Diluted	09.0	3.56			1.22	
	-	7000 00		A. T. A.				

Date: January 09, 2025

M. Kalyan Ram

Whole Time Director DIN:02012580

Vivo Bio Tech Limited

Your Drug Discovery Partner

Notes:

- 1. The above Un-Audited Financial Results for the Third Quarter and Nine Months ended December 31, 2024, were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on January 09, 2025.
- 2. The Un-Audited Financial Results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of Companies Act, 2013 ('The Act') read with relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3. The Consolidated Results include results of all subsidiaries, viz., Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited, Surlogic Life Consultancy Private Limited and Vivobio Consulting Services Private Limited (Formerly Donakanti Consulting Services Private Limited).
- 4. Company has Four (4) subsidiaries, viz., Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited, Surlogic Life Consultancy Private Limited and Vivobio Consulting Services Private Limited and has no associate/joint venture company(ies), as on December 31, 2024.
- 5. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required.
- 6. The above financial results are available on the stock exchange website www.bseindia.com and company's website www.vivobio.com.
- 7. Previous year's/period's figures are rearranged/ regrouped wherever necessary.

Date: January 09, 2025

Place: Hyderabad

For Vivo Bio Tech Limited

M. Kalyan Ram Whole Time Director

DIN: 02012580



Tel. : (91-40) 2332 6666, 2331 2554 (91-40) 2339 3967, 2332 1470

(91-40) 2332 2119, 2331 7032 Fax: (91-40) 2339 2474

Email: pmurali.co@gmail.com info@pmurali.com

Website: www.pmurali.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review report to The Board of Directors VIVO BIO TECH LIMITED

We have reviewed the accompanying statement of unaudited standalone financial results of M/s. VIVO BIO TECH LIMITED (the "Company") for the quarter ended 31 December, 2024 and for the period from 01 April 2024 to 31 December 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ('Ind AS 34,') prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





Tel.: (91-40) 2332 6666, 2331 2554 (91-40) 2339 3967, 2332 1470

(91-40) 2332 2119, 2331 7032

Fax: (91-40) 2339 2474 Email: pmurali.co@gmail.com info@pmurali.com

Website: www.pmurali.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali& Co., Chartered Accountants

FRN: 007257S

M V Joshi Partner

M. No. 024784

UDIN: 25024784BMIXQS1429

Place: Hyderabad Date: 09.01.2025



Tel.: (91-40) 2332 6666, 2331 2554 (91-40) 2339 3967, 2332 1470 (91-40) 2332 2119, 2331 7032

Fax: (91-40) 2339 2474

Email: pmurali.co@gmail.com info@pmurali.com

Website : www.pmurali.com

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended

Review report to The Board of Directors VIVO BIO TECH LIMITED

We have reviewed the accompanying statement of unaudited consolidated financial results of VIVO BIO TECH LIMITED (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended 31 December, 2024 and for the period from 01 April 2024 to 31 December 2024 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Tel.: (91-40) 2332 6666, 2331 2554 (91-40) 2339 3967, 2332 1470 (91-40) 2332 2119, 2331 7032

Fax: (91-40) 2339 2474

Email: pmurali.co@gmail.com info@pmurali.com

Website: www.pmurali.com

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities which are audited by us:

1. Vivo Bio Labs Private Limited

2. Vivo Bio Discovery Services Private Limited

3. Surlogic Life Consultancy Private Limited

4. Vivo Bio Consulting Services Private Limited (Formerly known as Donakanti Consultancy Services Private Limited)

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali& Co.

Chartered Accountants

FRN: 007257S

M V Joshi Partner

M.No. 024784

UDIN: 25024784BMIXQT2465

derabac

Place: Hyderabad Date: 09.01.2025.